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Background: Magnetic resonance-guided high-intensity focused ultrasound
(MRgHiFUS) has evolved into a viable ablative treatment option for functional
neurosurgery. However, it is not clear yet, how this new technology should be
integrated into current and established clinical practice and a consensus should be
found about recommended indications, stereotactic targets, patient selection, and
outcome measurements.
Objective: To sum up and unify current knowledge and clinical experience of Swiss
neurological and neurosurgical communities regarding MRgHiFUS interventions for brain
disorders to be published as a national consensus paper.
Methods: Eighteen experienced neurosurgeons and neurologists practicing in
Switzerland in the field of movement disorders and one health physicist representing
15 departments of 12 Swiss clinical centers and 5 medical societies participated
in the workshop and contributed to the consensus paper. All experts have
experience with current treatment modalities or with MRgHiFUS. They were invited
to participate in two workshops and consensus meetings and one online meeting.
As part of workshop preparations, a thorough literature review was undertaken and
distributed among participants together with a list of relevant discussion topics.
Special emphasis was put on current experience and practice, and areas of
controversy regarding clinical application of MRgHiFUS for functional neurosurgery.
Stieglitz et al. HiFUS Consensus Statement
Results: The recommendations addressed lesioning for treatment of brain disorders
in general, and with respect to MRgHiFUS indications, stereotactic targets, treatment
alternatives, patient selection and management, standardization of reporting and
follow-up, and initialization of a national registry for interventional therapies of movement
disorders. Good clinical evidence is presently only available for unilateral thalamic
lesioning in treating essential tremor or tremor-dominant Parkinson’s disease and, to
a minor extent, for unilateral subthalamotomy for Parkinson’s disease motor features.
However, the workgroup unequivocally recommends further exploration and adaptation
of MRgHiFUS-based functional lesioning interventions and confirms the need for
outcome-based evaluation of these approaches based on a unified registry. MRgHiFUS
and DBS should be evaluated by experts familiar with both methods, as they are
mutually complementing therapy options to be appreciated for their distinct advantages
and potential.
Conclusion: This multidisciplinary consensus paper is a representative current
recommendation for safe implementation and standardized practice of MRgHiFUS
treatments for functional neurosurgery in Switzerland.
Keywords: focused ultrasound, HIFUS, MRgHiFUS, consensus, movement disorders, Parkinson, tremor
INTRODUCTION
Magnetic resonance-guided high-intensity focused ultrasound
(MRgHiFUS) provides a novel ablative treatment option
currently applied mainly for essential tremor (ET) and to a
lesser extent for tremor-dominant Parkinson’s disease (PD) (1,
2). However, adoption of MRgHiFUS into clinical standard
of care and present revival of ablative interventional therapy
in functional neurosurgery raises a host of challenges for the
neurosurgical and neurological community. For MRgHiFUS
interventions with a relatively solid data basis of clinical
experience, standardization of patient selection and assessment,
time point for therapy, treatment targets and alternatives,
procedural details, patient management before, during and after
MRgHiFUS, outcome measurements, and benchmarking are
highly needed.
Functional neurosurgical treatment of brain disorders
requires multidisciplinary collaboration among various clinical
specialties. Apparent elegance of MRgHiFUS technology and
simplicity of intervention processes make it easy to forget
about the complexity of the pathophysiology of tremor. With
the expected sharp rise in MRgHiFUS intervention numbers
and given that MRgHiFUS is only at the beginning of its
technological maturation curve, it is important that all specialists
involved in care and management of patients suffering from
neurological and psychiatric disorders have access to up-to-
date information about the relevant technical and medical
peculiarities of MRgHiFUS-based interventional therapy.
Many issues concerning application of MRgHiFUS in
functional neurosurgery remain controversial, whereas currently
no clear guidelines regarding MRgHiFUS treatment exist. In
order to aggregate and harmonize current clinical knowledge
and experience regarding state-of-the art therapy of various
movement and pain disorders with a special focus on
MRgHiFUS, two complementary workshops and consensus
meetings in Zurich as well as one additional online meeting were
held, gathering participants from most of the specialized centers
for the treatment of movement disorders in Switzerland.
Here we present the consensus statement on clinical
application of MRgHiFUS for functional neurosurgery
as formulated by the newly established Swiss MRgHiFUS
Working Group.
Current Status
Although focused ultrasound has been applied as a neurosurgical
tool for more than 70 years (3), only the recent introduction of
modern MRgHiFUS devices finally allowed routine precise and
safe ablation of targets located deep inside the brain through the
intact skull (4).
The only commercially available transcranial MRgHiFUS
system (ExAblate NeuroTM; INSIGHTEC Ltd., Tirat Carmel,
Israel) consists of a phased array piezoceramic helmet with
1,024 elements that can precisely focus ultrasound waves
into circumscribed brain locations. A 1.5 or 3 Tesla MRI
scanner (GE Healthcare, Chicago, IL, USA and Siemens
Healthineers, Erlangen, Germany) for target verification, real-
time thermal feedback and treatment planning, guidance and
lesion confirmation complete the MRgHiFUS equipment.
MRgHiFUS has emerged as a neurosurgical option mainly
for the therapy of movement disorders (1, 2) but also for pain
syndromes (5). The procedure received FDA clearance with MRI
scanners from GE Healthcare in the USA for ET and PD in 2016,
and CE marking additionally for Siemens Healthineers MRI
systems in the European Community for neurological disorders,
specifically ET, tremor-dominant PD and neuropathic pain in
2018. Studies on novel indications such as psychiatric diseases,
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epilepsy and brain tumors, and on blood brain barrier opening
for targeted drug delivery against neurodegenerative diseases and
brain tumors are underway (6).
In Switzerland, three centers, the University Hospitals Zurich
and Geneva, and the SoniModul AG Solothurn, are offering
MRgHiFUS interventions in a clinical setting. In Zurich, clinical
applications of MRgHiFUS in the brain have been studied
since 2006 and, as early as 2009, the first focused ultrasound
interventions in the central lateral nucleus of the thalamus for
chronic neuropathic pain as a pilot application were reported (7).
Consensus Meetings and Workshops
Invitation
Motivated by the installation of a new clinical treatment
system for MRgHiFUS at the University Hospital Zurich and
the imminent addition of MRgHiFUS functional neurosurgery
interventions into the reimbursement catalog of the Swiss
public health system, the Swiss Movement Disorders Society
(SMDS) board decided to develop a set of guidelines for the
reintroduction of basal ganglia ablative functional neurosurgery
in Switzerland with MRgHiFUS technology. The guidelines
should build on the experience of movement disorders specialists
from classical radiofrequency lesioning, deep brain stimulation
(DBS) andMRgHiFUS and accordingly, a workgroupwas formed
(Swiss MRgHiFUS Working Group) involving neurologists,
neurosurgeons and medical physicists from all over Switzerland.
Invitations to participate in the meetings were sent to all
involved experts in Switzerland (1) all chairmen of neurological
departments of Swiss university hospitals and cantonal hospitals,
(2) all heads of movement disorders units in Switzerland,
(3) all neurologists and neurosurgeons already performing
MRgHiFUS treatments in Switzerland, and (4) all members of
the SMDS (see Participants for more details about the invitation
process). For workshop preparation, participants received a
booklet containing a list of all participants and their affiliations,
a comprehensive literature research and overview over the
pertinent publications on MRgHiFUS and basic information
about MRgHiFUS technology (see Selection of literature for
literature selection). The literature was selected by the organizing
committee, LS, GK and AK, and comprised the literature cited
in this manuscript. Furthermore, they were invited to provide
suggestions for key questions and topics to be discussed. The
objectives of the meetings and the consensus statement were to
provide a specialist framework and guidance to those embarking
on MRgHiFUS therapy including patient selection, indication,
procedure, aftercare, alternatives, and educational opportunities,
to discuss and highlight the potential, challenges, benefits
and distinctive risks of MRgHiFUS, and to promote scientific
activities and participation into clinical trials and registries.
Participants
All known experts in the field of movement disorders in
Switzerland were contacted via direct e-mail by the first author
(LS). In total 19 experts from 15 centers and members of 5
societies across Switzerland participated in the two workshops
and consensus meetings and the online meeting, comprising
14 neurologists, 4 neurosurgeons and 1 medical physicist. Nine
of the participants had personal experience with MRgHiFUS
treatment. Summarizing the Hôpital Fribourgeois (HFR),
Hôpitaux Universitaires de Genève (HUG), Center Hospitalier
Universitaire Vaudois (CHUV), Kantonsspital Aarau (KSA),
Universitätsspital Zürich (USZ), Luzerner Kantonsspital
(LUKS), Kantonsspital St. Gallen (KSSG), Neurocenter
of Southern Switzerland EOC Inselspital Bern, Zentrum
für Neurorehabilitation Zihlschlacht, Kliniken Valens, and
Kinderspital Zürich, all regions of Switzerland are represented
(Figure 1).
Selection of Literature
The selection of the literature followed PRISMA guidelines and
is illustrated in Figure 2. The process of literature selection was
repeated before the third meeting to cover recent publications,
which were not discussed during the first two meetings. Only
clinical papers were selected, purely technical and pre-clinical
studies were excluded. The search terms were chosen very
unspecific (“FUS” and “MR”) to avoid accidental exclusion of
relevant literature. All records were viewed by the organizing
team (LS, AK and GK) for exclusion of all records not related to
transcranial MRgHiFUS treatment. As a last step, all remaining
articles were reviewed for citations of relevant articles which were
not listed so far.
Workshop
The workshops and consensus meetings took place in Zurich on
2.12.2019 and 17.01.2020, respectively, in the form of moderated,
interdisciplinary roundtable discussions. A third meeting was
held online on 26.07.2021 to comply with the hospital regulations
of the Covid-19 pandemic.Meetingminutes were recorded by the
first author (LS) and reviewed by all participants.
The first meeting was moderated by a Swiss journalist, former
redactor and director of a large Swiss media company and advisor
for several Swiss cantonal health directors, who was booked




The process of the consensus meetings is illustrated in Figure 3.
The meetings followed a modification of the Nominal group
technique (8). The participants were asked to brainstorm in
private and provide their results to the organizing team. Those
topics were again distributed among the participants before the
meeting together with an overview of the relevant literature.
During the first two meetings, those topics were again enriched
through a second. Afterwards each of the topics was discussed
in plenum, followed by open voting (hand-raising) to generate
a common statement. The statements were collected by LS and
drafted into a statement manuscript, which was again re-read
and evaluated by all conference members before clearance for
dissemination. As there were many important results published
before finalization of the consensus statement, a third conference
was held in which the most recent literature was considered and
updated after another voting. The evidence level of the expert
commission’s statements is IV.
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FIGURE 1 | Process of invitation for constitution of the MRgHiFUS workgroup.
FIGURE 2 | Process of literature research and dissemination to workshop participants.
Topics and Questions
During October 2019 and January 2020, the organizers drafted a
meeting agenda including a list of relevant topics and questions
to be discussed by the new Swiss MRgHiFUS Working Group.
Based on a comprehensive literature review, special emphasis
was put on current experience and practice, and areas of
controversy regarding clinical application of MRgHiFUS for
functional neurosurgery. All participants were asked to provide
additional topics for the conference which were disseminated
among the group together with the relevant literature in advance.
CONSENSUS STATEMENT
Reintroduction of Lesioning
Should lesioning (irrespective of modality) be considered a viable
treatment option for movement disorders despite the success of
reversible DBS?
After the introduction of DBS, Professor Alim-Louis Benabid,
one of the pioneers of DBS, claimed he would never perform
a lesion again in a diseased brain (personal recollection of a
conversation by one of the authors). However, initial clinical
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FIGURE 3 | Overview over the process used by the Swiss MRgHiFUS Working Group for definition of topics, consolidation of an expert group and developing
consensus on MRgHiFUS treatment in Switzerland.
success and technological potential of MRgHiFUS warrant
reopening a therapy field that was considered closed.
Technically, the innovations distinguishing MRgHiFUS from
radio-frequency ablation (RFA) is (i) incisionless delivery of
therapy, (ii) intraoperative image guidance, (iii) intraoperative
ablation control, and (iv) progressive and better-controlled
ablation. Together, they enable a more precise ablation of small
functional targets deep in the brain which, owing to improved
anatomical and pathophysiological understanding, are much
clearer defined than in the initial days of lesioning. Compared
with radiosurgery (e.g., Gamma knife, GKRS), thermal lesions
created by MRgHiFUS become immediately effective and allow
both intra-operative image-based and neurological assessments
of induced lesions.
While physiologically thermal lesions created by RFA and
MRgHiFUS are similar, they differ in spatial geometry with
MRgHiFUS lesions being much sharper delineated than RFA.
Therefore, it will be challenging to translate previous clinical
experience and literature from RFA interventions toward
new MRgHiFUS lesioning. Most importantly, modern image
guidance will help reduce adverse effects from mistargeting and
will require an unbiased reevaluation of stereotactic targets both
in terms of therapeutic benefit and in terms of associated risks.
Evidence
The effects of MRgHiFUS on brain tissue are well-known and
it could be histologically demonstrated, that an ablative effect
is reached beyond a specific threshold over 50◦C (9). De Vloo
et al. used the opportunity to perform microelectrode recording
in a patient who underwent unsuccessful MRgHiFUS treatment
reaching only subtherapeutic temperatures. They found normal
cell activity and argued, that this finding supports the expectation
of not harming brain tissue below a threshold of 55◦C (10).
Dallapiazza et al. compared the results of DBS, MRgHiFUS,
GKRS and RFA in a systematic review and found evidence, that
indeed the use different technologies in the same targets leads to
comparable results (11).
Expert Opinion
The workgroup unequivocally recommends further exploration
and adaptation of MRgHiFUS-based functional lesioning
interventions as a complement and possible alternative to
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TABLE 1 | Summary of the core recommendation for the use of MRgHiFUS.
Indication MRgHiFUS-based ablative interventions are a complement to existing functional neurosurgery treatment approaches such as DBS
Essential tremor (ET) and tremor-dominant PD are presently the only indications for MRgHiFUS treatments with good level of
evidence
Neuropathic pain and PD with mostly unilateral motor symptoms are promising potential new indications and are under investigation
Clinical setting MRgHiFUS treatment should only be conducted in centers where conservative and alternative surgical treatment options like DBS
can be offered as well and where the therapy can be evaluated by multidisciplinary boards
Patient selection Thorough pre-interventional assessment of motor and non-motor symptoms is mandatory
MRgHiFUS should be considered in patients who present with contraindications for DBS
In addition, patient selection should start focusing on individual risk-benefit evaluations between MRgHiFUS, DBS and
other modalities
Procedure To prevent unsuccessful treatment attempts, unintended off-target ablations and damage to skin and bone marrow, deep knowledge
of the technical aspects of MRgHiFUS is mandatory and each patient must be evaluated thoroughly for eligibility for this kind of




Contraindication to high field MRI




Necessity to perform under general anesthesia
Low SDR
Relevant medical conditions such as low back pain, camptocormia, short neck and obesity
Presence of gait disorder
Targets Unilateral VIM or CTT for ET and tremor in PD
All other targets should be considered as experimental and be examined in clinical studies
Bilateral lesioning Presently not recommended
In exceptional cases, contralateral treatment should be staged at least six months after initial MRgHiFUS and the second treatment
only considered in absence of side effects from the initially treated side
Long-term efficacy Not known yet, maximal published follow-up is 4 years
existing treatment approaches such as DBS and confirms
the need for outcome-based standardized evaluation of these
approaches based on a unified registry.
Indications for MRgHiFUS
For which indications should MRgHiFUS be included into
standard of care; which indications should require further
evaluation in clinical trials and for which indications should
application of MRgHiFUS be discouraged?
Technically, MRgHiFUS can create small thermal lesions in
the thalamus and subthalamic area. Larger targets, or targets
that are located deeper or more peripherally, could potentially
also be accessed, but might need prolonged treatment times or
adapted patient positioning. Obvious candidates for MRgHiFUS
treatments are therefore patients with most indications that are
currently treated interventionally, especially with DBS:
• tremor (ET and PD tremor) by ventral intermediate thalamic
nucleus (VIM) lesioning
• PDwith fluctuations and dyskinesias by unilateral subthalamic
nucleus (STN) lesioning
• dystonia by bilateral globus pallidus internus (GPi) lesioning
• chronic neuropathic pain by centromedian thalamus (CMT)
and central lateral thalamus (CLT) lesioning
• psychiatric disorders such as OCD with anterior limb of
internal capsule (ALIC) lesioning
ET
Evidence
Recent randomized controlled studies (RCTs) have shown that
MRgHiFUS treatment works well for ET (2, 12, 13). According
to the currently available data (14), unilateral DBS and unilateral
MRgHiFUS in the VIM seem to be equally effective in ET.
For thalamic DBS, in some cases long-term habituation was
reported. The underlying mechanisms are not clear so far (15).
For thalamic RFA, habituation was not reported so far (16, 17).
Of course, the data available for DBS is far more extensive than
that for MRgHiFUS and thus a direct head-to-head comparison
is impossible yet. To identify, whether habituation is solely a topic
in DBS and not in MRgHiFUS, more evidence is needed.
Expert Opinion
Because of its proven effectivity and low complication rates,
MRgHiFUS could develop from a second-choice treatment
option for patients with contraindication to DBS into a preferred
option for a very specific sub-group of patients (class Ia evidence
for MRgHiFUS thalamotomy in ET). F.i. patients with only mild
tremor severity (partially refractory to medications, disabling
from the patient’s perspective, but too low to justify the risks of
DBS) might be a good choice as well as patients of advanced
age (too old for DBS), or patients with very asymmetric tremor
involving the dominant hand.
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With ET being mainly an isolated disease with typically only
low neurological comorbidity, MRgHiFUS could be offered by




Unilateral MRgHiFUS lesioning of VIM for tremor-dominant
PD has received FDA clearance in 2018 and seems to be a
viable treatment option (18). With published experience from
RFA predicting significant risk of side effects for bilateral
treatments, bilateral lesioning of the VIM or STN should not
be conducted outside RCTs until careful evaluation of outcome
data allows separation of risk factors, such as mistargeting or
bad target selection from patient-specific, respectively, disease-
related causes.
Recently, the effective reduction of motor features in PD
with asymmetrical medically refractory motor signs and/or
fluctuations by unilateral subthalamotomy using MRgHiFUS
technique was shown in a randomized controlled trial with
low complication rates, although new-onset dyskinesia during
the on- and off-state has been observed in some patients
(19). Another approach represents the unilateral pallidotomy
in PD patients with L-dopa responsiveness and asymmetrical
fluctuations and dyskinesias. Eisenberg et al. published a non-
controlled open-label trial in 20 patients with 59% improvement
of UDysRS in on-medication state and low complication
rates (20).
Expert Opinion
Because tremor is only a facet of the complex PD pathology,
the further course of the disease must be considered when
evaluating patients and selecting ablation targets. Although
the first results of subthalamotomy and pallidotomy in PD
patients are promising, the selection of patients for unilateral
treatment will be of key importance (class Ib evidence
for subthalamotomy and pallidotomy in PD). Involvement
of a specialized neurological department, offering alternative
treatments such as conservative therapy, drug delivery pumps or
DBS, is mandatory. Beside neurological, also neuropsychological
and neuropsychiatric expertise needs to be integrated, typically in
the form of multidisciplinary boards.
Dystonia
Evidence
For the treatment of dystonia, only a single case of MRgHiFUS
ablation in the ventral oral anterior thalamic nucleus (VOA)
has been reported so far. Although it might be a potential
indication, further studies are needed despite the technical
and medical challenges involved in conducting the intervention
(21). Most probably, interventions would require patients
to be anesthetized to ensure proper immobilization, leaving
neurological monitoring to minimal assessment of adverse
effects. In addition, MRgHiFUS treatment of GPi may even cause
PD-like side effects or even induce a parkinsonian syndrome
(22). A conceivable target would be the VOA, especially because
of promising data of previous thalamotomies (23, 24). First
experiences with pallidotomy in PD patients indicate, that the
technical issues might be solvable, and the side effects and
complications may be low (20).
Expert Opinion
Ablative treatment of dystonia has an interesting potential.
The key issue will be the safety of the procedure. Currently,
only very little experience exists with MRgHiFUS pallidotomies,
therefore the risk/benefit ratio may not be estimated properly.
Thus, treatments should only be performed within randomized
controlled trials. Based on the paucity of experience so far (class
IIb evidence for MRgHiFUS pallidotomy in PD), MRgHiFUS




Therapy-resistant pain was one of the first indications treated
with MRgHiFUS (7). The treatment of chronic neuropathic pain
(type 2) by RFA and MRgHiFUS is effective and well-established.
Experience with MRgHiFUS for pain is reported from the
consortium although few of the Swiss data is systematically
evaluated and published so far. Therefore, the currently available
data is sparse and insufficient. Different targets are appropriate,
among them the CMT or ventroposteromedial thalamic nucleus
(VPM) and ventroposterolateral thalamic nucleus (VPL) (5).
Lesioning of the VPM and VPL could be associated with
sensory deficits and therefore, the CMT should be preferred.
Alternatively, the lateral portion of the cuneocerebellar tract
(CCT) could be used.
Expert Opinion
No general recommendation can be made for patients suffering
from chronic pain. Indications for treatment including
MRgHiFUS should be restricted to the confines of RCTs




Regarding epilepsy therapy and targeting of e.g., the anterior
thalamic nucleus (ANT)withMRgHiFUS, no relevant data exists,
no experience was reported, and this therapy therefore currently
remains widely hypothetical and experimental. Lesioning the
ANT might be a promising option in therapy-resistant epilepsy.
Still, this would be a completely novel treatment and should only
be performed within the confines of a study protocol.
Expert Opinion
Beside ET and tremor-dominant PD, MRgHiFUS treatments for
movement disorders and other brain disorders in general are still
under clinical evaluation or even considered experimental.
Obsessive-Compulsive Disorder
Evidence
For cases of intractable OCD, DBS as well as ablative
neurosurgery have been tried as escalation therapies (25). Among
the ablative techniques, only gamma ventral capsulotomy was
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examined in an RCT with a response in 3/8 patients at 12 months
and 5/8 patients at 54 months and no severe complications,
indicating that ventral capsulotomy is a viable alternative to
DBS in selected cases (26, 27). A recent phase I trial published
by Davidson et al. reported a response in 4/6 patients after
MRgHiFUS ventral capsulotomy inOCDpatients with no serious
adverse events (class IIb evidence) (28).
Expert Opinion
Treatment of intractable OCD with ventral MRgHiFUS
capsulotomy might be efficacious. So far, only very small studies
have been published and a sufficiently long follow-up seems to
be crucial to correctly evaluate the efficiency of the treatment.
Furthermore, ventral capsulotomy must be evaluated against
DBS, for which more experience is published from randomized
controlled trials. At the given time, treatment of intractable OCD
with MRgHiFUS should be restricted to the confines of RCTs.
Clinical Setting for MRgHiFUS
In which clinical settings should MRgHiFUS be performed?
Evidence
There is presently no evidence available regarding required
clinical settings for MRgHiFUS.
Expert Opinion
Therapeutically, MRgHiFUS is an incisionless, ablative
procedure involving low but real risks of neurological
complications and adverse effects due to unintentional effects
to non-targeted functional units, unexpected side effects of
network modulation and, most significantly, microscopic
and macroscopic bleeding. It is therefore considered essential
that MRgHiFUS treatments are conducted under supervision
of experienced functional neurosurgeons and specialized
neurologists. Furthermore, centers offering MRgHiFUS should
have an adequate access to emergency neurosurgery and
anesthesiology, and neurointensive or intermediate care. This
means that centers offering MRgHiFUS treatment must be able
to diagnose and treat emerging complications autonomously
by providing permanent availability of experts from different
disciplines and professions like neurology, neuroradiology,
neuro-intensive care, and physiotherapy. Furthermore, an
adequate patient selection requires a multidisciplinary team
for the evaluation of the patient before the intervention,
including assessment of motor and non-motor symptoms, e.g.,
cognitive impairment not allowing the adequate communication
during MRgHiFUS.
Hence, MRgHiFUS treatment should only be conducted
in clinical settings where multiple treatment options can
be offered and where therapy options can be evaluated by
multidisciplinary movement disorder boards, which usually are
located at specialized centers and university hospitals.
Patient Selection for MRgHiFUS
Which patient groups could benefit most from MRgHiFUS?
Evidence
So far, all randomized controlled studies on MRgHiFUS selected
patients who were in one way or another not suitable for DBS
(1, 2).
Expert Opinion
During its clinical introduction, MRgHiFUS has been considered
an interventional treatment option mainly for patients who
presented with contraindications for DBS. Such cases could
include patients not tolerating electrode implants, patients not
able to adequately handle the DBS devices, or patients with
brain pathologies not eligible for insertion of electrodes and
DBS. With clinical acceptance of the method, patient selection
can start focusing on individual risk-benefit evaluations between
MRgHiFUS, DBS and othermodalities. Therapeutically, themain
difference between MRgHiFUS and DBS-based modulation of
neuronal circuits is the permanent nature of thermal lesions,
which cannot be altered once they are set, respectively, can
only be increased in size if not effective enough. Accordingly,
patient selection should focus on patients where post-operative
optimization of intervention outcome is not a priority or where
the underlying pathology is not expected to require repeated
adaptation of network modulation in the near future such as
PD. In terms of indications, ET seems a good indication for
MRgHiFUS because it mostly does not follow a course of multi-
systemic progression such as PD and even improved albeit
residual tremor can result in good quality of life (QoL). In terms
of patient cohorts, MRgHiFUS could be an attractive option
for elderly patients in general, where improving prominent
symptoms might provide significantly increased QoL within the
relevant time horizon. It should be noted that the lack of post-
interventional effect tuning goes together with reduced clinical
time and effort and accordingly reduced financial burden for the
healthcare system.
Safety Procedures and Contraindications
for MRgHiFUS
Which safety procedures and contraindications should be respected
to ensure maximum patient safety during the procedures?
Technical Aspects
Evidence
The efficiency of focusing acoustic energy into a circumscriptive
target inside the skull for thermal ablation depends strongly
on the acoustic properties of the patient skull which have
high inter-individual variability. A rough estimate of expected
focusing quality is provided by the skull density ratio (SDR),
which is calculated from preoperative computed tomography
data of the patient’s head. Typical SDR values for Caucasian
patients are between 0.45 and 0.80, whereas SDR should not
have values below 0.35 for thalamic targets and 0.4 for extra-
thalamic targets such as the GPi. Low SDR values imply
poor focusing quality, i.e., less precise lesion definition and
compensating for associated low focusing gain will require higher
acoustic energies, leading to more skull heating with the risk of
unintended damage to skull bone-marrow. Ultimately, under-
treated stereotactic targets because of insufficient total thermal
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dose are a risk (29). Pathological deformations of skull shape,
skull bone replacements and other artifacts of past surgical
interventions may reduce usable skull surface to a degree where
inacceptable skull heating might occur.
Expert Opinion
Knowing and respecting ultrasound physics and the limits
of the technique is essential to prevent possibly harming the
patients either by insufficient treatment, which then needs to be
repeated with other techniques, or treatment side effects. Thus,
MRgHiFUS should only be performed in a center providing the
needed technical expertise and support.
Patient Cooperation
Evidence
To the best of the authors’ knowledge, there is no data available
regarding the need for cooperation of the patients during
MRgHiFUS treatment.
Expert Opinion
MRgHiFUS interventions are conducted by repeating sonications
with stepwise increased energy levels and resulting peak
temperatures at target to allow constant evaluation of intended
treatment effects and unintended side effects. Patient cooperation
for neurological testing is therefore essential and reliable two-way
communication between treatment team and patient is required.
Treatments under general anesthesia would technically be
possible, but the lack of neurological testing as a means of target
verification might increase the risk for complications due to
mistargeting or excessive lesion size. Therefore, such treatments
are discouraged for the time being.
Patient Medical Status
Evidence
The authors are not aware of any published experiences regarding
MRgHiFUS under effective anticoagulation or antiaggregation.
Microbleeds in the core of the lesion, on the other hand, are
regularly observed by neuroimaging (30, 31).
Expert Opinion
Although MRgHiFUS does not require a skin incision or skull
trepanation, the energy applied to the skull and brain via
ultrasound waves is invasive. Associated risks include cavitation
effects to blood-vessels and to the margins of intracranial cysts
like Virchow-Robin spaces. Consequently, though the risk of
intracranial hemorrhage may be low, normal coagulation status
and absence of any antiaggregatory or anticoagulative therapy
must be assured preoperatively. The risk for convulsive epileptic
seizures during the treatment should be low as such an event
could endanger the patient when occurring with the head
fixed in a stereotactic frame. Furthermore, the risk of severe
nausea and vomiting due to sonic stimulation of somatosensory
pathways in the thalamus should be considered and addressed
properly. Administration of antiemetics prior to the treatment
and ensuring a slow and careful passage of the patient into
and out of the magnetic resonance imaging (MRI) scanner’s
static magnetic field are preventive measures. The presence of an
anesthesiologist to immediately treat severe nausea by providing
suction of the oral cavity in case of emesis is advisable as draining
the water and taking the patient out of the treatment device
may take too long. Lastly, lower-back pain, camptocormia, a
short neck and obesity must be considered during evaluation of
patients for MRgHiFUS therapy.
MRI Contraindications, Implants, Scars
Evidence
Only few scientific evidences are available about MRgHiFUS
contraindications due to local pathology. Yang et al. published a
technical note and report of one patient who receivedMRgHiFUS
thalamotomy for ET despite an implanted VP shunt. They
found no adverse effects and only a small number of elements
which had to be switched off to prevent damaging the shunt
components (32).
Expert Opinion
Obviously, all contraindications for high-field MRI apply, such
as MRI-incompatible medical implants, claustrophobia, inability
to lay prone for extended periods of time, etc. should be
thoroughly considered. In addition, scars in the scalp may lead to
trapped air bubbles on the skin surface hindering the treatment.
Old trepanations, craniotomies or cranioplasties must be also
considered during intervention planning and frame fixation to
prevent accidental heating, skin burns, off-target tissue ablation
and skull fractures or impressions. For cranial implants like CSF
shunts, there is limited experience available so far, although such
implants, if generally MR compatible, might not necessarily be
a strict contraindication. The safety of the patients should be
considered extremely carefully, cases be published and unusual
conditions registered in a registry.
Targets for MRgHiFUS
Should MRgHiFUS lesioning apply the same stereotactic targets as
currently established for DBS?
Evidence
There is a lack of comparative studies of DBS, RFA, MRgHiFUS,
and radiosurgical ablations, but in a thorough meta-analysis
of the published results of all these techniques, Dallapiazza et
al. found comparable response rates and complication rates,
indicating that indeed the same targets which apply for DBS may
apply for MRgHiFUS (11).
Expert Opinion
Functionally, MRgHiFUS lesions and DBS should elicit
comparable neurological effects if placed identically in spite of
the different mechanisms of action and even though further
studies are needed to understand better specific mechanisms of
action of DBS. However, the methods differ in their flexibility
to access and cover functional targets and in their risk profiles
for inducing side effects. If targets are within the accessible
volume dictated by ultrasound physics, MRgHiFUS theoretically
can create lesions of any size or form by combining successive
point lesions and therefore could paint anatomical structures
for optimal target coverage. However, doing so can be very
time consuming and transient edema associated with thermally
induced lesions might lead to intra- and postoperative adverse
Frontiers in Neurology | www.frontiersin.org 9 September 2021 | Volume 12 | Article 722762
Stieglitz et al. HiFUS Consensus Statement
effects that resolve only after days or weeks. In addition, off-
target tissues could accumulate enough thermal dose during the
process to get permanent thermal damage. DBS on the other
hand, can adapt the geometry of the stimulation field around
the electrode to optimize treatment effect and over time can
follow disease dynamics. Furthermore, new DBS technique
using “closed loop” modulation of the stimulation (intensity and
duration) could better adapt to symptoms variability (33, 34).
Still, limitations of field shaping due the specific geometry of
contacts might lead to excess stimulation of surrounding tissues




The efficacy of MRgHiFUS thalamotomy of the VIM in ET was
shown in randomized controlled trials (2, 14, 35). Gallay et al.
reported a series of 50 cerebellothalamic tract (CTT) lesions
(and several other targets and indications) with MRgHiFUS
with low complication rates (36). Boutet et al. found the best
effect after lesioning the most posterior portion of the Vim
in a retrospective analysis of 66 cases (37) and Pineda-Pardo
et al. correlated microstructural changes to the dentato-rubro-
thalamic tract (equates CTT) with a good response of tremor
after lesioning (38). The evidence level is Ib. The best location is
probably the entry of the CTT into the thalamus, i.e., just below
the VIM itself.
Expert Opinion
Regarding essential tremor, in principle the same targets used
for DBS could be also applied for MRgHiFUS. The VIM surely
represents a suitable and established target with a favorable risk
profile (39). Additionally, positive experiences with the CTT
in DBS were reported by members of the group and might
be considered as an alternative target especially in cases of
decreasing clinical effect after VIMMRgHiFUS.
PD
Evidence
Bond et al. published the results of a randomized controlled trial
on MRgHiFUS thalamotomy of the VIM for tremor dominant
PD in 2017, showing good tremor response and low side effects
(1). The evidence level is Ib. Martínez-Fernández et al. just
recently published a randomized controlled trial of unilateral
STN ablations in highly asymmetrical PD with good results
(evidence level Ib). So far, there is no published controlled study
on pallidotomy for PD (19).
Expert Opinion
Aside from unilateral VIM lesioning for tremor-dominant PD,
lesioning of the pallidothalamic tract (PTT), as an alternative
to VIM, could lead to decreased responsiveness to L-Dopa
medication. Therefore, even unilateral MRgHiFUS of that target
may lead to freezing, dysarthria, and dysphagia in patients at risk.
Lesioning the GPi is difficult as it is located more lateral and
closer to the outer margin of the brain volume less accessible to
the MRgHiFUS system. Patients with relatively low SDR (below
0.4) might not qualify for such a treatment.
In summary, MRgHiFUS lesioning cannot be presently
applied to all stereotactic targets as currently established for DBS.
Only CCT and VIM can be considered as established targets and
all others should be further investigated in prospective controlled
clinical studies.
Bilateral Treatments With MRgHiFUS
Experiences with and risk evaluation for bilateral ablative
treatment in terms of recommended indications and
temporal staging?
Evidence
Technically, MRgHiFUS allows for bilateral treatments, both
within the same treatment session, or in a staged manner during
two consecutive sessions. Reasons for simultaneous bilateral
treatments could be to increase therapeutic effects, f. i. for
neuropathic pain, or to save patients from the burden of multiple
hospitalizations. Staged bilateral treatments could be considered
to extend therapeutic benefit to the contralateral side or in case of
axial symptoms like head or voice tremor. In addition, multiple
functional targets could be applied to try regulating pathologic
brain function via multiple pathways.
Current literature from RFA and DBS describes potential
risks of bilateral treatments which are considered also relevant
for MRgHiFUS (40). In particular, experience from earlier
pallidotomy demonstrate that bilateral lesioning may harbor the
risk of considerable side effects (e.g., corticobulbar syndrome,
apathy, falls etc.) (37). Recent publication of a retrospective
case-series of 9 patients with ET and another prospective series
of 10 ET patients who received staged bilateral thalamotomies
showed a good therapeutic effect on both sides with only low
complication rates. Careful patient selection and exclusion of
patients with pre-existing gait disorders was found to be key for
the treatment success (41, 42). The evidence level is IIb.
Expert Opinion
If applied, treatments should be staged at least three, better even
6 months after initial MRgHiFUS and the second treatment
only considered in absence of side effects from the initially
treated side. Overall, bilateral treatments are still considered
experimental. Risk-benefit evaluation will depend strongly on
indications, targets to be assessed and symptomatic patient status.
Standardization of Patient Evaluation for
MRgHiFUS
How should pre- and post-interventional examinations and
assessments for MRgHiFUS patients be standardized?
Evidence
There is no relevant data and evidence available on this topic.
Expert Opinion
For reasons of comparability and integration of registries
pre- and post-interventional evaluations of MRgHiFUS patients
should be carefully standardized using state-of-the art assessment
tools and internationally accepted norms. Wherever applicable,
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MRgHiFUS and DBS interventions should be assessed using
identical protocols except for intervention-specific data.
Long-Term Efficacy of MRgHiFUS
What should we expect for long-term treatment outcomes
after MRgHiFUS?
Evidence
MRgHiFUS lesioning is still a relatively new treatment
and consequently, knowledge about long-term treatment
outcome is limited. The longest follow-up data published
so far demonstrated efficacy for up to 4 years (2, 5, 35, 43).
Anatomically, it is well-documented that MRgHiFUS lesions
created at moderate peak temperatures and moderate
accumulated thermal dose can become completely invisible
in MRI some 12 months post intervention. As a general rule
and in strong contrast to radiation lesions, thermal MRgHiFUS
lesions show their largest extension in MRI 24–48 h post
intervention and from then on shrink both in T2 and in T1
imaging. However, functionally, deactivated neurons cannot
be replaced, and long-term efficacy of ablative interventions
will depend both on brain plasticity, that is, the capacity
to recruit new neurons within damaged networks, and on
the extent of progressing neurodegeneration and associated
emergence of new pathologic network activity. For ET the
problem of possible tolerance to DBS treatment after years
is not reported so far in the case of RFA or MRgHiFUS-
generated lesions (11). Long-term follow-up of tremor patients
treated with MRgHiFUS ablation will be essential in the
future to evaluate these two treatment concepts against
each other.
Expert Opinion
Continued evaluation of the patients who were enclosed
in RCTs to learn about long-term efficacy of MRgHiFUS
treatment is one important step but will not provide
generalizable data easily. The method will also have to
prove its worth in comparison with the treatment gold-
standard. The best way to provide the required data for
these observations is to include as many cases as possible in
national or even international registries. One problem still
unsolved is the heterogeneity of the used endpoints in studies
and registries.
DISCUSSION
The primary objective of the workshops and consensus
meetings was to discuss in-depth the current status of
MRgHiFUS and to provide guidance to those involved
in MRgHiFUS therapy. Secondarily, it was aimed to
evaluate the potential benefits, specific challenges, and
distinctive risks of this novel technology, and to promote
further clinical and scientific exchange of experience
and outcome data. Finally, by establishing the Swiss
MRgHiFUS Working Group, an interdisciplinary network
for MRgHiFUS and future clinical and scientific collaboration
was created.
This article describes issues that are relevant and of potential
interest not only for MRgHiFUS experts, but also for general
practitioners, neurologists and neurosurgeons and provides
consensus-based recommendations in key areas of uncertainty. A
number of questions currently remain unaddressed or could not
be completely answered and therefore corresponding studies are
highly desired. A priority for this research regards experimental
indications such as chronic neuropathic pain andOCD. Carefully
designed clinical studies will be required to optimally integrate
these interventions into currently available treatment strategies.
It should be noted that the current recommendations
were formulated by medical professionals practicing in the
setting of the national Swiss healthcare system which might
affect their generalizability to a broader patient population
outside Switzerland. Still, Switzerland was among the first
countries to introduce MRgHiFUS treatment and has already
longstanding experience in that field. One more important
limitation of the present consensus statement is that it does
not provide a similarly high level of evidence such as a
systematic review but relies on the experiences and opinions
of a group of experts. The members of the Swiss MRgHiFUS
workgroup think that at the given time the number of available
RCTs is still too small to justify a systematic review. The
consensus statement deemed to be the proper method as
it added the experience of a group of experts, which is
representative for Switzerland, to today’s available evidence.
As the number of publications on MRgHiFUS is growing
exponentially, the consensus statements were outdated already
when the manuscript was first drafted. To provide a timely
statement, a third conference was held, which dealt with recent
developments and publications.
It is expected that the evidence included in the article and
consensus-based recommendations will be helpful and provide
valuable guidance for clinicians and healthcare professionals
involved in the treatment of patients with MRgHiFUS.
CONCLUSION
These recommendations (Table 1) are based on current literature
and clinical experience and aim to serve as a primer for
harmonizing and optimizing patient management and best
clinical practice regarding MRgHiFUS therapy in Switzerland.
The vivid discussions confirmed the need for regular meetings
and information exchange among the specialists in the field
involved in the diagnosis and therapy of disorders treatable by
functional neurosurgery. As is apparent from this manuscript,
many topics need further elaboration and integration of future
clinical experience.
It also became apparent that DBS and MRgHiFUS should
not be treated in separate communities and should not be
played off against each other. Rather, they should be adopted
as mutually complementing therapy options that should be
appreciated for their distinct advantages and therapy potential to
further extend the therapeutic spectrum and optimize as well as
tailor patient treatment.
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